Cosmo Bio Co., Ltd.

As of June 30, 2026, Cosmo Bio Co., Ltd. carries a market capitalization of 7.00B, placing it among publicly traded companies globally. Its enterprise value stands at 3.54B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Cosmo Bio Co., Ltd.'s next confirmed earnings release is scheduled for November 6, 2026.

As of June 30, 2026, Cosmo Bio Co., Ltd. has 5.70M shares outstanding.

These figures are as of June 30, 2026.

As of June 30, 2026, Cosmo Bio Co., Ltd. maintains a current ratio of 7.34, meaning it holds 7.3x the short-term assets needed to cover near-term liabilities.

These figures cover the twelve months ended June 30, 2026.

As of the close on October 22, 2026, Cosmo Bio Co., Ltd.'s stock has gained approximately 3.36% over the past 52 weeks. The 50-day moving average sits at 1,248.62, while the 200-day moving average is 1,273.05.

As of June 30, 2026, Cosmo Bio Co., Ltd. holds 4.07B in cash and equivalents against 20.00M in total debt, resulting in a net debt position of -3.45B. Total book value stands at 9.76B, with working capital of 6.85B providing operational flexibility.

Cosmo Bio Co., Ltd.'s most recent stock split took place on December 26, 2012 with a 1:100 split ratio.